Ken Griffin Tempest Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Tempest Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 27,500 shares of TPST stock, worth $23,100. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,500
Previous 29,600
7.09%
Holding current value
$23,100
Previous $64,000
40.63%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding TPST
# of Institutions
34Shares Held
2.4MCall Options Held
44.9KPut Options Held
109K-
Black Rock Inc. New York, NY550KShares$462,2020.0% of portfolio
-
Altium Capital Management LP New York, NY545KShares$457,8000.27% of portfolio
-
Geode Capital Management, LLC Boston, MA220KShares$184,8560.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA176KShares$148,0020.0% of portfolio
-
Fil LTD Hamilton, D0130KShares$108,8460.0% of portfolio
About Tempest Therapeutics, Inc.
- Ticker TPST
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,418,900
- Market Cap $8.75M
- Description
- Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxiso...